# A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

> **NCT06855160** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 900 (estimated)

## Conditions studied

- Chickenpox

## Interventions

- **BIOLOGICAL:** Candidate varicella vaccine
- **BIOLOGICAL:** Marketed varicella vaccine
- **BIOLOGICAL:** MMR vaccine
- **BIOLOGICAL:** Hepatitis A vaccine
- **BIOLOGICAL:** PCV (pneumococcal conjugate vaccine) 13
- **BIOLOGICAL:** PCV 20
- **BIOLOGICAL:** Vaxneuvance

## Key facts

- **NCT ID:** NCT06855160
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2026-09-10
- **Final completion:** 2027-02-02
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06855160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06855160, "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06855160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*